Market research
ALT Altimmune Inc
NASDAQ USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 399M
- P/E ratio
- Not available
- Analyst target
- 17.1111
- Dividend yield
- Not available
- Beta
- 0.06
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 399M
- P/E ratio
- Not available
- Analyst target
- 17.1111
- Dividend yield
- Not available
- Beta
- 0.06
About
About Altimmune Inc
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Research context
Altimmune Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ALT discussion.
5 years, 6 months ago
Altimmune, Inc is currently in a long term downtrend where the price is trading 35.4% below its 200 day moving average.
From a valuation standpoint, the stock is 96.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 43.9.
Altimmune, Inc's total revenue rose by 301.7% to $2M since the same quarter in the previous year.
Its net income has dropped by 159.3% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 576.3% to $-14M since the same quarter in the previous year.
Based on the above factors, Altimmune, Inc gets an overall score of 2/5.